AU2021343534A1 - TREATMENT OF NF-κB-MEDIATED DISEASE - Google Patents
TREATMENT OF NF-κB-MEDIATED DISEASE Download PDFInfo
- Publication number
- AU2021343534A1 AU2021343534A1 AU2021343534A AU2021343534A AU2021343534A1 AU 2021343534 A1 AU2021343534 A1 AU 2021343534A1 AU 2021343534 A AU2021343534 A AU 2021343534A AU 2021343534 A AU2021343534 A AU 2021343534A AU 2021343534 A1 AU2021343534 A1 AU 2021343534A1
- Authority
- AU
- Australia
- Prior art keywords
- human patient
- day
- vamorolone
- muscular dystrophy
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063081073P | 2020-09-21 | 2020-09-21 | |
| US63/081,073 | 2020-09-21 | ||
| US202163195473P | 2021-06-01 | 2021-06-01 | |
| US63/195,473 | 2021-06-01 | ||
| US202163214908P | 2021-06-25 | 2021-06-25 | |
| US63/214,908 | 2021-06-25 | ||
| PCT/US2021/051274 WO2022061287A1 (en) | 2020-09-21 | 2021-09-21 | TREATMENT OF NF-κB-MEDIATED DISEASE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021343534A1 true AU2021343534A1 (en) | 2023-05-11 |
| AU2021343534A9 AU2021343534A9 (en) | 2024-10-17 |
Family
ID=80776432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021343534A Pending AU2021343534A1 (en) | 2020-09-21 | 2021-09-21 | TREATMENT OF NF-κB-MEDIATED DISEASE |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220184098A1 (https=) |
| EP (1) | EP4213855A4 (https=) |
| JP (1) | JP2023543439A (https=) |
| KR (1) | KR20230092905A (https=) |
| AU (1) | AU2021343534A1 (https=) |
| CA (1) | CA3170698A1 (https=) |
| IL (1) | IL301500A (https=) |
| MX (1) | MX2023003258A (https=) |
| WO (1) | WO2022061287A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4436583A4 (en) * | 2021-11-22 | 2025-04-02 | ReveraGen BioPharma, Inc. | TREATMENT OF NF-kB-MEDIATED DISEASE |
| WO2025199347A1 (en) * | 2024-03-21 | 2025-09-25 | Reveragen Biopharma, Inc. | Treatment of glomerulonephritis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006279325B2 (en) * | 2005-08-18 | 2013-06-27 | Accelalox, Inc. | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway |
| CA2855756A1 (en) * | 2011-11-29 | 2013-06-06 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of nf-kb for treatment of disease |
| WO2014205045A1 (en) * | 2013-06-18 | 2014-12-24 | Downes, Michael | Methods of treating muscular dystrophy |
| PL4023222T3 (pl) * | 2015-09-08 | 2025-03-24 | The Children's Hospital Of Philadelphia | Nieselektywny aktywator metabotropowych receptorów glutaminianu do leczenia zespołu 22q |
| US11382922B2 (en) * | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
-
2021
- 2021-09-21 WO PCT/US2021/051274 patent/WO2022061287A1/en not_active Ceased
- 2021-09-21 JP JP2023518416A patent/JP2023543439A/ja active Pending
- 2021-09-21 MX MX2023003258A patent/MX2023003258A/es unknown
- 2021-09-21 KR KR1020237013258A patent/KR20230092905A/ko active Pending
- 2021-09-21 IL IL301500A patent/IL301500A/en unknown
- 2021-09-21 AU AU2021343534A patent/AU2021343534A1/en active Pending
- 2021-09-21 EP EP21870412.0A patent/EP4213855A4/en active Pending
- 2021-09-21 CA CA3170698A patent/CA3170698A1/en active Pending
-
2022
- 2022-02-21 US US17/651,879 patent/US20220184098A1/en not_active Abandoned
-
2023
- 2023-08-14 US US18/449,312 patent/US20240139210A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022061287A1 (en) | 2022-03-24 |
| JP2023543439A (ja) | 2023-10-16 |
| KR20230092905A (ko) | 2023-06-26 |
| US20220184098A1 (en) | 2022-06-16 |
| CA3170698A1 (en) | 2022-03-24 |
| MX2023003258A (es) | 2023-05-08 |
| IL301500A (en) | 2023-05-01 |
| EP4213855A4 (en) | 2024-10-23 |
| EP4213855A1 (en) | 2023-07-26 |
| US20240139210A1 (en) | 2024-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220249515A1 (en) | Ganaxolone for use in treating genetic epileptic disorders | |
| JP7819094B2 (ja) | ヒトアミノステロールｅｎｔ－０３化合物、それを含む関連組成物、およびそれを使用する方法 | |
| TW202128183A (zh) | 用於治療多種病症之方法及組成物 | |
| US20240139210A1 (en) | Treatment of nf-kb-mediated disease | |
| US20240245711A1 (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder | |
| AU2023220976A1 (en) | Neuroactive steroids for treatment of cns-related disorders | |
| JP2023539567A (ja) | 神経活性ステロイドを含有する医薬組成物及びその使用 | |
| JP7607577B2 (ja) | ピリダジノンｔｒｐｃ５阻害剤の噴霧乾燥された製剤 | |
| US20240299416A1 (en) | TREATMENT OF NF-kB-MEDIATED DISEASE | |
| AU2024204716A1 (en) | Treatment of alopecia areata | |
| US20240226117A1 (en) | Treatment of congenital adrenal hypoplasia | |
| CN116507338A (zh) | NF-κB介导的疾病的治疗 | |
| AU2019386235A1 (en) | Montelukast for the treatment of erosive hand osteoarthritis | |
| JP2024527992A (ja) | 神経刺激性ステロイドの結晶形 | |
| CN117098554A (zh) | 用于治疗重度抑郁障碍的19-去甲c3,3-二取代c21-n-吡唑基类固醇 | |
| EA052165B1 (ru) | Ганаксолон для использования в лечении наследственных эпилептических заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |